أعرض في EDS

The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

التفاصيل البيبلوغرافية
العنوان: The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
المؤلفون: E. Gez, Howard I. Scher, Gedske Daugaard, Brieuc Sautois, Josep M. Piulats, Simon Paul Watkins, Wassim Abida, Laurence Eliot Miles Krieger, Charles J. Ryan, Andrew Simmons, Florence Joly, Raymond S. McDermott, Alejo Rodriguez-Vida, Cora N. Sternberg, K. Fizazi, S. Shetty, T. Golsorkhi, J.A. Arranz Arija, Srikala S. Sridhar, Simon Chowdhury, Axel S. Merseburger, Axel Heidenreich, Jeremy Shapiro
المصدر: European Urology Supplements. 16:e2689-e2690
بيانات النشر: Elsevier BV, 2017.
سنة النشر: 2017
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Pathology, business.industry, Urology, Castration resistant, medicine.disease, Clinical trial, Prostate cancer, chemistry.chemical_compound, chemistry, Internal medicine, PARP inhibitor, medicine, In patient, Rucaparib, Homologous Recombination Deficiency, business
تدمد: 1569-9056
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3a39a3f95ca1ab9d1debd9ed8bdf0e69
https://doi.org/10.1016/s1569-9056(17)31836-5
حقوق: CLOSED
رقم الأكسشن: edsair.doi...........3a39a3f95ca1ab9d1debd9ed8bdf0e69
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15699056